Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 638 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 1998  |  Volume : 2  |  Issue : 2  |  Page : 36-43

Evaluation Of Efficacy And Safety Of Gliclazide in NIDDM Patients Who Failed To Respond To Glibenclamide Therapy

Correspondence Address:
T Ramesh Kumar

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

The safety and efficacy of gliclazide, 80 mg twice daily was evaluated in NIDDM patients who failed to respond to 10mg or more of glibenclamide. Two hundred ad twenty seven patients were evaluated in eight centres. Fasting blood glucose was reduced by >20% in 36% and HbA1c by more than 12.5% in 74% of patients at the end of 12 weeks of treatment. The responders to both a reduction of fasting blood glucose >20% and HbA1c by more than or equal to 12.5% were 32% of patients. There was a significant reduction in total serum cholesterol (p<0.01), triglycerides (p<0.05) and LDL (p<0.01) at the end of 12 weeks. The incidence of side effects was 6.2%.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded131    
    Comments [Add]    

Recommend this journal